Evidence map›Paper›PMID 32290418›Full record

ArticleCancers2020

Reconstruction of Ewing Sarcoma Developmental Context from Mass-Scale Transcriptomics Reveals Characteristics of EWSR1-FLI1 Permissibility.

Henry E Miller, Aparna Gorthi, Nicklas Bassani, Liesl A Lawrence, Brian S Iskra, Alexander J R Bishop

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. NAR genomics and bioinformatics · 2023
    Article
  13. Complex/crypticGenes · 2023
    Article
  14. Article
  15. Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  16. Article
  17. RLSuite: An Integrative R-Loop Bioinformatics Framework.Journal of bioinformatics and systems biology : Open access · 2023
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Henry E MillerDepartment of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0003-3756-3918
Aparna GorthiDepartment of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Nicklas BassaniGreehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Liesl A LawrenceDepartment of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Brian S IskraDepartment of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Alexander J R BishopDepartment of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-5742-4387
The University of Texas Health Science Center at San Antonio · US

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
Cancer Biology Training ProgramT32CA148724 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Pei Wang, Feng-Chun Yang · 2011 to 2026
$3.3M
Dysregulated transcription processes in Ewing sarcoma:R01CA241554 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BISHOP, ALEXANDER JAMES · 2020 to 2025
$2.3M
NRSA Training Core (TL1)TL1TR002647 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHUN, YONG-HEE PATRICIA, FREI, CHRISTOPHER R. · 2018 to 2022
$1.8M
Improving etoposide treatment of Ewing's sarcomaR01CA152063 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BISHOP, ALEXANDER JAMES · 2011 to 2015
$1.5M
High Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
$600k
Targeting Doxorubicin-Induced Mitochondrial Failure in Mesenchymal Stem Cells with MetforminF30AG057213 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ISKRA, BRIAN · 2017 to 2021
$188k
NCATS NIH HHS TL1 TR002647NCATS NIH HHS TL1TR002647NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA152063NCI NIH HHS R01 CA241554NCI NIH HHS T32 CA148724NCI NIH HHS T32CA148724NIA NIH HHS F30 AG057213NIH HHS 1R01CA152063NIH HHS 1R01CA241554NIH HHS 1S10OD021805-01NIH HHS P30CA054174NIH HHS T32GM113896 / STXMSTPNIH HHS TL1TR002647
6 · The paper itself

Abstract

Ewing sarcoma is an aggressive pediatric cancer of enigmatic cellular origins typically resulting from a single translocation event t (11; 22) (q24; q12). The resulting fusion gene,

Indexed as

cell identitydevelopmental trajectoriesEwing sarcomaEWSR1-FLI1manifold learningreplication stressR-loopssarcomagenesissingle cell biologytranscriptomics

Identifiers

PMID32290418
PMCPMC7226175
OpenAlexW3015261626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.